Aurobindo Pharma Limited — Q2 FY26
Aurobindo Pharma reported Q2 FY26 consolidated revenue of INR 8,286 crore (+6% YoY) and EBITDA of INR 1,678 crore (20.3% margin, +7% YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
China facility to break even at EBITDA by Q3 FY26
The China facility, with initial capacity of 2 billion+ units, is expected to break even at EBITDA level by Q3 FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY26
PNG plant to generate healthy EBITDA from Q3 FY26
The PNG plant resumed operations and is expected to generate healthy EBITDA from Q3 onwards as yields improve.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1